#HVO hVIVO PLC – Appointment of Non-Executive Chair September 1, 2025 – Posted in: hVIVO (HVO) – Tags: aim, avacta, board, clinical, clinigen. CRO, kintiga, NED trials
Appointment of Non-Executive Chair
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that, further to its announcement on 29 July 2025, Shaun Chilton has today joined the Board of Directors as Non-Executive Chair with immediate effect.
Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group.
Elaine Sullivan, Interim Chair & Senior Non-Executive Director of hVIVO plc, said: “We are delighted to welcome Shaun to the Board of hVIVO. Shaun brings a wealth of sector-relevant experience and we believe his expertise will support us as we continue to grow and diversify the Group. As a Board we look forward to working closely with Shaun to help deliver on the Company’s mission and execute on our strategy.”
Shaun Chilton, incoming Non-Executive Chair of hVIVO plc, said: “I am pleased to join the Board of hVIVO plc, a Company which I believe has excellent prospects as it continues to diversify its service offering while leading the global charge in delivering exceptional human challenge trial services to its clients.”
Additional Information on the Board Appointment
The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged 57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:
|
Current directorships/partnerships: |
Former directorships/partnerships (within the last five years): |
|
Avacta Group plc |
C7 Health Limited |
|
Bellbrook Consulting Limited |
Clinigen Clinical Trials Limited |
|
Mustang Bidco Limited |
Clinigen Consulting Limited |
|
Mustang Midco Limited |
Clinigen CTS Limited |
|
Mustang Topco Limited |
Clinigen Gap Limited |
|
Clinigen Healthcare Limited |
|
|
Clinigen Holdings Limited |
|
|
Clinigen International Holdings Limited |
|
|
Clinigen Limited |
|
|
Clinigen Pharma Limited |
|
|
Definigen Limited |
|
|
IDIS GA Limited |
|
|
IDIS Group Holdings Limited |
|
|
IDIS Group Limited IDIS Limited |
|
|
IDIS MA Limited |
|
|
IDIS Pharma Limited |
|
|
Iovance Biotherapeutics UK SP Ltd |
|
|
Keats Healthcare Limited |
Shaun does not hold any shares or options in the Company.
There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
For further information please contact:
|
hVIVO plc |
+44 (0)20 7756 1300 |
|||
|
Yamin ‘Mo’ Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer |
||||
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0)20 7220 0500 |
|||
|
Geoff Nash, Callum Davidson Nigel Birks – Life Science Specialist Sales Louise Talbot – Sales |
||||
|
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 |
|||
|
James Steel, Dr Christopher Golden |
||||
|
Davy (Joint Broker) |
+353 (0) 1 679 6363 |
|||
|
Anthony Farrell, Niall Gilchrist |
||||
|
Walbrook PR (Financial PR & IR) Paul McManus / Alice Woodings Lianne Applegarth |
+44 (0)20 7933 8780 or hvivo@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7407 804 654 +44 (0)7584 391 303 |
|||